127 related articles for article (PubMed ID: 27967239)
1. Lipid Osteoclastokines Regulate Breast Cancer Bone Metastasis.
Krzeszinski JY; Schwaid AG; Cheng WY; Jin Z; Gallegos ZR; Saghatelian A; Wan Y
Endocrinology; 2017 Mar; 158(3):477-489. PubMed ID: 27967239
[TBL] [Abstract][Full Text] [Related]
2. CD137 promotes bone metastasis of breast cancer by enhancing the migration and osteoclast differentiation of monocytes/macrophages.
Jiang P; Gao W; Ma T; Wang R; Piao Y; Dong X; Wang P; Zhang X; Liu Y; Su W; Xiang R; Zhang J; Li N
Theranostics; 2019; 9(10):2950-2966. PubMed ID: 31244935
[No Abstract] [Full Text] [Related]
3. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
[TBL] [Abstract][Full Text] [Related]
5. Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis.
Pollari S; Käkönen SM; Edgren H; Wolf M; Kohonen P; Sara H; Guise T; Nees M; Kallioniemi O
Breast Cancer Res Treat; 2011 Jan; 125(2):421-30. PubMed ID: 20352489
[TBL] [Abstract][Full Text] [Related]
6. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice.
Nakamura H; Hiraga T; Ninomiya T; Hosoya A; Fujisaki N; Yoneda T; Ozawa H
J Bone Miner Metab; 2008; 26(6):642-7. PubMed ID: 18979165
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
9. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
10. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF.
Park BK; Zhang H; Zeng Q; Dai J; Keller ET; Giordano T; Gu K; Shah V; Pei L; Zarbo RJ; McCauley L; Shi S; Chen S; Wang CY
Nat Med; 2007 Jan; 13(1):62-9. PubMed ID: 17159986
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer metastasis to bone: it is not all about PTHrP.
Bendre M; Gaddy D; Nicholas RW; Suva LJ
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S39-45. PubMed ID: 14600591
[TBL] [Abstract][Full Text] [Related]
12. Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis.
Siclari VA; Mohammad KS; Tompkins DR; Davis H; McKenna CR; Peng X; Wessner LL; Niewolna M; Guise TA; Suvannasankha A; Chirgwin JM
Breast Cancer Res; 2014 Dec; 16(6):458. PubMed ID: 25439669
[TBL] [Abstract][Full Text] [Related]
13. Metastatic breast cancer induces an osteoblast inflammatory response.
Kinder M; Chislock E; Bussard KM; Shuman L; Mastro AM
Exp Cell Res; 2008 Jan; 314(1):173-83. PubMed ID: 17976581
[TBL] [Abstract][Full Text] [Related]
14. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
Hiraga T; Myoui A; Choi ME; Yoshikawa H; Yoneda T
Cancer Res; 2006 Feb; 66(4):2067-73. PubMed ID: 16489006
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer.
Futakuchi M; Fukamachi K; Suzui M
Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):206-211. PubMed ID: 26656603
[TBL] [Abstract][Full Text] [Related]
17. Gut-derived serotonin induced by depression promotes breast cancer bone metastasis through the RUNX2/PTHrP/RANKL pathway in mice.
Zong JC; Wang X; Zhou X; Wang C; Chen L; Yin LJ; He BC; Deng ZL
Oncol Rep; 2016 Feb; 35(2):739-48. PubMed ID: 26573960
[TBL] [Abstract][Full Text] [Related]
18. Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis.
Rafiei S; Tiedemann K; Tabariès S; Siegel PM; Komarova SV
Cancer Lett; 2015 Jun; 361(2):262-70. PubMed ID: 25779674
[TBL] [Abstract][Full Text] [Related]
19. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
20. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation.
Coenegrachts L; Maes C; Torrekens S; Van Looveren R; Mazzone M; Guise TA; Bouillon R; Stassen JM; Carmeliet P; Carmeliet G
Cancer Res; 2010 Aug; 70(16):6537-47. PubMed ID: 20682798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
